Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) (NCT07053709) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD)
200 participantsStarted 2026-11-01
Plain-language summary
Due to the established correlation between serum uric acid (SUA) levels and metabolic associated fatty liver disease (MAFLD), this study aims to screen for hyperuricemia in all patients diagnosed with MAFLD.
The ultimate goal is to support the management of MAFLD and improve patients' quality of life by reducing both morbidity and mortality.
Who can participate
Age range18 Years – 60 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adults aged over 18 years.
* Diagnosis of MAFLD based on abdominal ultrasonography or other validated imaging techniques.
Exclusion Criteria:
* Patients aged 18 years or younger.
* Pregnant individuals.
* Presence of any malignancy.
* Diagnosis of type 1 diabetes mellitus (T1DM).
* Patients with fatty liver disease who have previously undergone bariatric surgery.
What they're measuring
1
Search for hyperuricemia in every patient with MAFLD
Timeframe: At diagnosis and follow up after 6 month
Trial details
NCT IDNCT07053709
SponsorAssiut University
Sponsor typeOTHER
Study typeOBSERVATIONAL
Primary completion2026-11-01
Contact for this trial
Amira M Abdelmawgod, lecturer in Tropical Medicine, MD, Assuit University